STOCK TITAN

Lexicon Pharmaceuticals Inc Stock Price, News & Analysis

LXRX Nasdaq

Welcome to our dedicated page for Lexicon Pharmaceuticals news (Ticker: LXRX), a resource for investors and traders seeking the latest updates and insights on Lexicon Pharmaceuticals stock.

Lexicon Pharmaceuticals Inc. (LXRX) delivers innovative genomic-driven therapies for chronic diseases through its proprietary drug discovery platform. This page provides centralized access to official press releases, clinical trial updates, and strategic developments from the biopharmaceutical innovator.

Investors and industry observers will find timely updates on key initiatives including neuropathic pain treatment LX9211, diabetes therapies, and cardiovascular research. The resource aggregates regulatory milestones, partnership announcements, and scientific presentations while maintaining strict compliance with financial disclosure standards.

All content undergoes verification against primary sources to ensure accuracy. Users can monitor developments across Lexicon's pipeline – from preclinical research to commercialized products like INPEFA® – through curated news streams free of promotional language.

Bookmark this page for efficient tracking of LXRX's progress in advancing non-opioid pain management solutions and targeted metabolic therapies. Regular updates provide critical insights into the company's position within the evolving biopharmaceutical landscape.

Rhea-AI Summary
Lexicon Pharmaceuticals (LXRX) presented post-hoc analysis data at the ADA's 85th Scientific Sessions showing that sotagliflozin, when added to insulin therapy, reduces hypoglycemic events in Type 1 diabetes patients. The analysis, based on inTandem 1 and 2 Phase 3 trials data, demonstrated that sotagliflozin treatment resulted in lower hypoglycemia rates compared to placebo, particularly in patients with blood glucose ≤55 mg/dL. The effect was consistent across different kidney function groups. This finding is significant as hypoglycemia accounts for 5% of T1D hospitalizations and up to 10% of T1D deaths, with chronic kidney disease affecting 20-40% of T1D patients being a major risk factor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.12%
Tags
none
-
Rhea-AI Summary
Lexicon Pharmaceuticals (LXRX) will present clinical data at the 85th ADA Scientific Sessions on June 20-23, 2025, in Chicago. The presentation focuses on sotagliflozin's ability to reduce hypoglycemic events in type 1 diabetes patients across different kidney function levels, categorized by eGFR ranges. Dr. M. Belinda Hardin will deliver an oral presentation on June 22 discussing these findings. Additionally, Lexicon will present topline results from their PROGRESS Phase 2b study of pilavapadin (LX9211), evaluating its effectiveness in treating diabetic peripheral neuropathic pain. The presentations align with ADA's 2025 Standards of Care emphasis on preventing hypoglycemia in type 1 diabetes management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.46%
Tags
conferences
-
Rhea-AI Summary

Lexicon Pharmaceuticals (NASDAQ: LXRX) announced its upcoming participation in the 2025 Jefferies Global Healthcare Conference. The company's management will engage in a fireside chat scheduled for Thursday, June 5 at 12:50 p.m. ET in New York City. Investors and interested parties can access both the live presentation and its replay through the Events section of Lexicon's investor relations website at https://investors.lexpharma.com/.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.66%
Tags
conferences
Rhea-AI Summary

Lexicon Pharmaceuticals (NASDAQ: LXRX) presented the design of its SONATA-HCM Phase 3 clinical trial at Heart Failure 2025, evaluating sotagliflozin for both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM). The study is actively enrolling 500 patients across 20 countries, with all sites expected to be operational by September 2025.

The trial aims to assess sotagliflozin's efficacy on symptoms, function, and patient-reported outcomes in HCM patients. The primary endpoint measures symptom improvement using the Kansas City Cardiomyopathy Questionnaire at week 26. Recent evidence published in The Lancet (February 2025) suggests sotagliflozin's dual SGLT1 and SGLT2 inhibition reduces major adverse cardiovascular events.

If successful, the study could support a supplemental new drug application (sNDA) for sotagliflozin in both HCM types, addressing a significant unmet need, particularly for non-obstructive HCM where no approved therapies exist.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
none
-
Rhea-AI Summary
Lexicon Pharmaceuticals (LXRX) reported Q1 2025 financial results and business updates. The company secured an exclusive license agreement with Novo Nordisk for LX9851, potentially worth up to $1 billion in payments. Their Phase 2b PROGRESS study confirmed 10 mg pilavapadin as the optimal dose for Phase 3 development in diabetic peripheral neuropathic pain. Q1 financial results showed revenues of $1.3 million, R&D expenses of $15.3 million, and reduced SG&A expenses to $11.6 million. Net loss improved to $25.3 million ($0.07 per share) from $48.4 million in Q1 2024. The company ended Q1 with $194.8 million in cash and investments. Lexicon is advancing multiple pipeline programs, including sotagliflozin for hypertrophic cardiomyopathy in the SONATA-HCM Phase 3 study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.57%
Tags
-
Rhea-AI Summary

Lexicon Pharmaceuticals (NASDAQ: LXRX) announced its participation in the upcoming 3rd Annual H.C. Wainwright BioConnect Investor Conference. The company's management will engage in a fireside chat scheduled for Tuesday, May 20, at 9:30 a.m. ET at the Nasdaq World Headquarters in New York City. Investors and interested parties can access both the live presentation and its replay through the Events section of Lexicon's investor relations website at https://investors.lexpharma.com/.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.44%
Tags
conferences
Rhea-AI Summary

Lexicon Pharmaceuticals (NASDAQ: LXRX) has scheduled its first quarter 2025 financial results announcement for Tuesday, May 13, 2025, after market close. The company will host a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) on the same day, where management will discuss the quarterly results and provide a business update. Interested participants can access the webcast through the Events page on Lexicon's investor website, while those wishing to ask questions during the call can register to receive dial-in information. An archived version of the webcast will be made available on the company's website for later viewing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.9%
Tags
conferences earnings
-
Rhea-AI Summary

Lexicon Pharmaceuticals (Nasdaq: LXRX) has announced its upcoming participation in the 24th Annual Needham Virtual Healthcare Conference 2025. The company's management will deliver a presentation on Wednesday, April 9, at 8:00 a.m. ET.

Investors and interested parties can access both the live event and a replay of the presentation through the Events section of Lexicon's investor relations website at https://investors.lexpharma.com/.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.4%
Tags
conferences
-
Rhea-AI Summary

Lexicon Pharmaceuticals (LXRX) has entered into an exclusive worldwide license agreement with Novo Nordisk for LX9851, a first-in-class oral non-incretin drug candidate targeting obesity and metabolic disorders. The deal includes potential payments of up to $1 billion, with $75 million in upfront and near-term milestone payments.

LX9851 is a selective oral small molecule inhibitor of ACSL5, targeting fat accumulation and energy balance regulation. Preclinical data from Obesity Week 2024 demonstrated that LX9851, when combined with semaglutide, significantly reduced weight, food intake, and fat mass compared to semaglutide alone. The drug also showed positive effects on liver steatosis and mitigated weight regain after semaglutide discontinuation.

Under the agreement, Novo Nordisk will handle IND filing, development, manufacturing, and commercialization, while Lexicon completes IND-enabling activities. Lexicon will receive tiered royalties on net sales in addition to milestone payments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
64.13%
Tags
none
Rhea-AI Summary

Lexicon Pharmaceuticals (Nasdaq: LXRX) has announced its upcoming participation in the Leerink Partners Global Healthcare Conference 2025 in Miami. The company's management will engage in a fireside chat scheduled for Wednesday, March 12, at 10:00 a.m. ET. Both the live presentation and a subsequent replay will be made available to interested parties through the Events section of Lexicon's investor relations website at investors.lexpharma.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.55%
Tags
conferences

FAQ

What is the current stock price of Lexicon Pharmaceuticals (LXRX)?

The current stock price of Lexicon Pharmaceuticals (LXRX) is $1.08 as of July 11, 2025.

What is the market cap of Lexicon Pharmaceuticals (LXRX)?

The market cap of Lexicon Pharmaceuticals (LXRX) is approximately 327.2M.
Lexicon Pharmaceuticals Inc

Nasdaq:LXRX

LXRX Rankings

LXRX Stock Data

327.22M
358.72M
1.19%
84.1%
13.13%
Biotechnology
Pharmaceutical Preparations
Link
United States
THE WOODLANDS